Lynch SyndromePhase 1/2PREVENT-LynchNCT07412197
Preventive Dendritic Cell Vaccination for Lynch Syndrome
A Phase 1/2 study testing DC vaccination in people with Lynch Syndrome, run by Radboud University Medical Center at 1 site in Netherlands.
Trial summary
The aim of this study is to assess safety, immunogenicity and feasibility of vaccination with neopeptide-loaded dendritic cells in Lynch Syndrome subjects who are known to be carrier of a germline MMR-gene mutation without signs of disease. Read more about this study
- Who is it for?
- Ages 35 to 75 years
- Conditions the study is for
- Lynch Syndrome
- What is being tested?
- DC vaccination
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 16 participants
- Where
- 1 siteNetherlands
- Study dates
- Oct 2026to Jun 2036
- Phase
- Phase 1/2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- a confirmed gPV in MLH1 or MSH2 and without a prior history of MMR-D cancer.
- a confirmed gPV in MSH6, whether or not they have a history of MMR-D cancer. MSH6 subjects with a history of MMR-D cancer have to be cancer-free for more than 1 year.
- previous surgical treatment may include any resection up to and including hemicolectomy; subjects who have undergone (sub)total colectomy are excluded due to the substantially reduced risk of cancer occurrence.
- aged between 35 and 75 for subjects with gPV in MLH1 and MSH2; and aged between 40 and 75 for subjects with gPV in MSH6.
- Lynch syndrome subjects without clinical signs of disease.
- Lynch syndrome subjects with a prior history of colorectal premalignancies with at least 1 adenoma sample archived.
Show all 20Show fewer
- Lynch syndrome subjects without prior treatment for LS-associated cancer, except for MSH6 subjects who are >1 year disease-free and whose prior surgical treatment did not include subtotal colectomy.
- Routine surveillance colonoscopy must be performed within 16 weeks prior to start of study, to exclude (pre)malignancy.
- HLA-A02.01 genotype
- Adequate hematologic, renal, and liver function as defined by laboratory values: WBC >3.0^109/l, lymphocytes >0.8^109/l, platelets >100^109/l, haemoglobin >7,0 mmol/l (9.0 g/dl), estimated glomerular filtration rate > 45 ml/min/1.73m2, AST/ALT <3 x ULN, serum crea¬tinine <150 µmol/l, serum bilirubin <1.5 x ULN (exception: Gilbert's syndrome is permitted).
- WHO performance status of 0 or 1
- No concomitant use of immunosuppressive drugs orally or intravenously. Topical and intranasal steroids are permitted.
- No uncontrolled infectious disease, i.e., negative testing for HIV, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and syphilis (Treponema Pallidum Hemagglutination Assay (TPHA)).
- No autoimmune disease such as, but not limited to, inflammatory bowel disease, multiple sclerosis, and lupus. Subjects with type 1 diabetes mellitus, hypothyroidism after autoimmune thyroiditis and skin disorders are not excluded.
- No serious (bleeding and clotting) condition that may interfere with safe leukapheresis.
- No pregnant or lactating women. hCG tests will be performed regularly during the trial to confirm absence of pregnancy.
- No Women Of Child-Bearing Potential (WOCBP) or male partners of WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for up to 8 weeks after the last administration of the treatment. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea > 12 consecutive months].
- Subjects must have absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions must be discussed with the subject before registration in the trial.
- Expected adequacy of follow-up.
- Written informed consent.
Who cannot join
- Individuals with a history of malignancy in the past. Allowed malignancies are adequately treated basal cell carcinoma and squamous cell carcinoma of the skin, carcinoma in situ (e.g., DCIS/LCIS/cervical CIS), papillary thyroid carcinoma, and low-risk prostate carcinoma; all locally resected with negative surgical margins and not treated with systemic therapy.
- Organ allografts.
- Known allergy to shellfish.
- Inability to understand and communicate in Dutch.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Targeting Cancer Neoantigens Through Multi-Epitope Vaccination for Tumour Prevention in Lynch Syndrome: a Phase I/II Clinical Trial.
The aim of this study is to assess safety, immunogenicity and feasibility of vaccination with neopeptide-loaded dendritic cells in Lynch Syndrome subjects who are known to be carrier of a germline MMR-gene mutation without signs of disease.
Read the detailed description
A single-centre, single-arm phase I/II clinical trial evaluating the safety and immunogeniticy of therapeutic multi-epitope vaccination targeting emergent cancer neoantigens for tumour prevention. The study will include LS subjects aged 35-75 who carry a confirmed germline MMR gene mutation (MLH1, MSH2, or MSH6) and have no clinical signs of disease. Participants will be followed for 36 months, with an additional 7 years of follow-up
- Conditions
- Lynch Syndrome
- Being tested
- DC vaccination
- Keywords
- Dendritic cells, Cancer vaccine, Hereditary cancer, Lynch Syndrome, Prevention, Neoantigens
- Medical subject headings
- Colorectal Neoplasms, Hereditary Nonpolyposis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DC vaccinationBiological
Subjects in the DC vaccination arm will receive a maximum of 2 cycles each consisting of 3 DC injections intranodally (3-7x10^6 DC)
| Study group | Role | What they receive |
|---|---|---|
| DC vaccination | Experimental | Subjects in the DC vaccination arm will receive a maximum of 2 cycles each consisting of 3 DC injections intranodally Receives: Biological: DC vaccination |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with Treatment-Related adverse events as assessed by CTCAE v5.0 (Safety)
Measured: 2 years
To assess whether neoantigen-specific T cells are induced by the DC vaccine (immunogenicity).
Immunogenicity will be assessed by the percentage of participants showing a neo-antigen-specific T cell response, defined by the expansion of T cells that recognize tumor antigens and demonstrate effector functions. Non-responders are those with no T cell expansion or insufficient immune activity.
Measured: 4 years
Secondary outcomes (3)
Disease-free survival
To evaluate whether LS subjects who develop a T cell response to a frameshift-derived neoantigen included in the vaccine have an improved DFS; defined as the time from the 1st vaccination until development of an MMR-D colorectal adenoma, any LS-associated carcinoma in situ, or any LS-associated carcinoma, or until follow up ends, whichever occurs first.
Measured: 10 years
Quality of Life Questionnaires
To evaluate whether LS subjects who develop a T cell response to a frameshift-derived neoantigen included in the vaccine have an improved QoL; defined as patient's self-perceived physical, psychological and social well-being in relation to their health status, assessed using questionnaires.
Measured: baseline, week 3, week 28, week 50, month 36, month 60, month 84, month 108
Number of participants successfully enrolled for manufacturing autologous DC product with sufficient yield for at least one injection intranodally (IN) for treatment purposes and one intradermally (ID) for diagnostic purposes(Feasibility)
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2026
- Study startOct 2026 (estimated)
- Primary completionDec 2029 (estimated)
- Study completionJun 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lynch SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 16 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Radboud University Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Dutch Cancer Society
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07412197
- Sponsor's protocol ID
- EU CT 2025-524046-10-00
- Acronym
- PREVENT-Lynch
- Status last verified
- Dec 2025
- First submitted
- 5 Feb 2026
- Last updated
- 19 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided